Riassunto
I tumori della testa e del collo (HNSCC) comprendono quelli che originano dall’epitelio del tratto prossimale delle vie aero-digestive (cavo orale, faringe, laringe, seni paranasali e ghiandole salivari); essi rappresentano la sesta causa di morte per cancro nel mondo [1].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Bibliografia
Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics. CA Cancer J Clin 55:74–108
D’Souza G, Kreimer AR, Viscidi R et al (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944–1956
Rampias T, Sasaki C, Weinberger P, Psyrri A (2009) E6 and E7 gene silencing and. transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 101:412–423
McCaul JA, Gordon KE, Clark LJ, Parkinson EK (2002) Telomerase inhibition and the future management of headand-neck cancer. Lancet Oncol 3:280–288
Goodwin EC, Naeger LK, Breiding DE et al (1998) Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines. J Virol 72:3925–3934
Munger K, Baldwin A, Edwards KM et al (2004) Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78:11451–11460
Mellin H, Dahlgren L, Munck-Wikland E et al (2002) Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 102:152–158
Van Tine BA, Dao LD, Wu SY et al (2004) Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning. Proc Natl Acad Sci USA 101:4030–4035
Goodwin EC, DiMaio D (2000) Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of donnant tumor suppressor pathways. Proc Natl Acad Sci USA 97:12513–12518
Tang S, Tao M, McCoy JP et al (2006) Short-term induction and long-term suppression of HPV 16 oncogene silencing by RNA interference in cervical cancer cells. Oncogene 25:2094–2104
de Villiers EM, Weidauer H, Otto H, zur Hausen H (1985) Papillomavirus DNA in human tongue carcinomas. Int J Cancer 36:575–578
Li Y, Nichols MA, Shay JW, Xiong Y (1994) Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p 16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54:6078–6082
Agoff SN, Lin P, Morihara J et al (2003) pl6(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of highrisk HPV types. Mod Pathol 16:665–673
Begum S, Gillison ML, Ansari-Lari MA et al (2003) Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9:6469–6475
Tan TM, Ting RC (1995) In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. Cancer Res 55:4599–4605
Strati K, Pitot HC, Lambert PF (2006) Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci USA 103:14152–14157
Smeets SJ, Hesselink AT, Speel EJ et al (2007) A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121:2465–2472
Slebos RJ, Yi Y, Ely K et al (2006) Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 12:701–709
Pyeon D, Newton MA, Lambert PF et al (2007) Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 67:4605–4619
Grandis JR, Tweardy DJ (1993) Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53:3579–3584
Karamouzis MV, Grandis JR, Argiris A (2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 298:70–82
Goldstein NI, Prewett M, Zuklys K et al (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311–1318
Ciardiello F, Tortora G (2002) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958–2970
Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression tissue microarrays. Nat Med 8:1323–1327
Psyrri A, Yu Z, Weinberger PM et al (2005) Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11:5856–5862
Lin SY, Makino K, Xia W et al (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3:802–808
Chung CH, Ely K, McGavran L et al (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24:4170–4176
Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043
Miller CT, Lin L, Casper AM et al (2006) Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 25:409–418
Sok JC, Coppelli FM, Thomas SM et al (2006) Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12:5064–5073
Amador ML, Oppenheimer D, Perea S et al (2004) An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64:9139–9143
Timpson P, Wilson AS, Lehrbach GM et al (2007) Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 67:9304–9314
Clark ES, Brown B, Whigham AS et al (2009) Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 1 1q13 amplicon. Oncogene 28:431–444
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Italia
About this chapter
Cite this chapter
Rampias, T., Psyrri, A. (2011). Biologia dei tumori squamocellulari. In: Tumori della testa e del collo. Springer, Milano. https://doi.org/10.1007/978-88-470-1806-8_7
Download citation
DOI: https://doi.org/10.1007/978-88-470-1806-8_7
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1805-1
Online ISBN: 978-88-470-1806-8
eBook Packages: MedicineMedicine (R0)